ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy

Lancet Respir Med. 2014 Dec;2(12):966-8. doi: 10.1016/S2213-2600(14)70259-0. Epub 2014 Nov 19.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Clinical Trials as Topic
  • Drug Resistance, Neoplasm / genetics
  • Gene Rearrangement
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / therapy
  • Molecular Targeted Therapy / methods*
  • Mutation / genetics
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / genetics*
  • Proto-Oncogene Proteins / genetics*
  • Receptor Protein-Tyrosine Kinases / genetics*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Protein-Tyrosine Kinases
  • ROS1 protein, human
  • Receptor Protein-Tyrosine Kinases